Protein Losing Enteropathy

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
ODSH at 0.125 mg/kg/hPhase 11 trial
Active Trials
NCT01161641Terminated5Est. Feb 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Jazz PharmaceuticalsODSH at 0.125 mg/kg/h

Clinical Trials (1)

Total enrollment: 5 patients across 1 trials

NCT01161641Jazz PharmaceuticalsODSH at 0.125 mg/kg/h

Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery

Start: Jul 2010Est. completion: Feb 20125 patients
Phase 1Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space